Rinaldi I, Winston K Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review. Journal of Blood Medicine. 2023:261– 77. https://doi.org/10.2147/JBM.S382090

Lin Q, Mao L, Shao L, Zhu L, Han Q, Zhu H et al (2020) Global, regional, and national burden of chronic myeloid leukemia, 1990–2017: a systematic analysis for the global burden of disease study 2017. Front Oncol 10:580759. https://doi.org/10.3389/fonc.2020.580759

Article  PubMed  PubMed Central  Google Scholar 

Hehlmann R (2020) Chronic myeloid leukemia in 2020. Hemasphere 4(5):e468. https://doi.org/10.1097/hs9.0000000000000468

Article  PubMed  PubMed Central  Google Scholar 

Mendizabal AM, Younes N, Levine PH (2016) Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia. Int J Hematol 103:70–78. https://doi.org/10.1007/s12185-015-1893-y

Article  PubMed  Google Scholar 

Jabbour E, Kantarjian H (2020) Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 95(6):691–709. https://doi.org/10.1002/ajh.25792

Article  PubMed  CAS  Google Scholar 

Benchikh S, Bousfiha A, El Hamouchi A, Soro SGC, Malki A, Nassereddine S (2022) Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution. Egypt J Med Hum Genet 23(1):29. https://doi.org/10.1186/s43042-022-00248-2

Article  Google Scholar 

García-Gutiérrez V, Hernández-Boluda JC (2019) Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol 9:603. https://doi.org/10.3389/fonc.2019.00603

Article  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917–927. https://doi.org/10.1056/NEJMoa1609324

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tavakoli S, Khalaj F, Kasaeian A, Mousavi SA, Mousavian A-H, Arabi F et al (2023) Comparable outcomes of Pre-versus Post-tyrosine kinase inhibitor era treatment in chronic myeloid leukemia: a Retrospective Cohort Study with Long-Term follow-up. Cell Transplant 32:09636897231163212. https://doi.org/10.1177/09636897231163212

Article  PubMed  PubMed Central  Google Scholar 

Andrews CN, Lipton J (2019) The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia. Lancet Haematol 6(8):e385–e6. https://doi.org/10.1016/s2352-3026(19)30112-7

Article  PubMed  Google Scholar 

Abou Zahr A, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R et al (2016) Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica 101(6):660. https://doi.org/10.3324/haematol.2015.141283

Article  CAS  Google Scholar 

Hamid A, Ashraf S, Qamar S, Naveed MA, Hameed A, Farooq MA (2019) Myelofibrosis in patients of chronic myeloid leukemia in chronic phase at presentation. J Coll Physicians Surg Pak 29:1096–1100. https://doi.org/10.29271/jcpsp.2019.11.1096

Article  PubMed  Google Scholar 

Pandey N, Yadav G, Kushwaha R, Verma SP, Singh US, Kumar A et al (2019) Effect of imatinib on bone marrow morphology and angiogenesis in chronic myeloid leukemia. Adv Hematol 2019(1):1835091. https://doi.org/10.1155/2019/1835091

Article  PubMed  PubMed Central  CAS  Google Scholar 

Eliacik E, Isik A, Aydin C, Uner A, Aksu S, Sayinalp N et al (2015) Bone marrow fibrosis may be an effective independent predictor of the ‘TKI drug response level’in chronic myeloid leukemia. Hematology 20(7):392–396. https://doi.org/10.1179/1607845414y.0000000221

Article  PubMed  CAS  Google Scholar 

Thiele J, Kvasnicka HM, Facchetti F, Franco V, van Der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90(8):1128–1132

PubMed  Google Scholar 

Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood cancer J 8(2):15. https://doi.org/10.1038/s41408-018-0054-y

Article  PubMed  PubMed Central  Google Scholar 

Shanmuganathan N, Branford S, Hughes TP, Hiwase D (2019) Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Blood Adv 3(3):370–374. https://doi.org/10.1182/bloodadvances.2018027516

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jacobi H, Vieri M, Bütow M, Namasu CY, Flüter L, Costa IG et al (2023) Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients. Front Pharmacol 14:1212392. https://doi.org/10.3389/fphar.2023.1212392

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kantarjian HM, Bueso-Ramos CE, Talpaz M, O’Brien S, Giles F, Rios MB et al (2005) The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 46(7):993–997. https://doi.org/10.1080/10428190500097581

Article  PubMed  CAS  Google Scholar 

Pepeler MS, Tıglıoglu M, Dagdas S, Ozhamamcıoglu E, Han U, Albayrak A et al (2024) Prognostic impact of bone Marrow Fibrosis and effects of tyrosine kinase inhibitors on bone marrow fibrosis in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 24(4):e161–e7. https://doi.org/10.1016/j.clml.2023.12.015

Article  PubMed  CAS  Google Scholar